Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
$13.04
-6.3%
$11.61
$4.88
$19.58
$302.01MN/A79,752 shs49,370 shs
Cybin Inc. stock logo
CYBN
Cybin
$7.63
-3.0%
$7.64
$4.81
$13.88
$175.67M0.69281,668 shs525,058 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$14.12
+3.9%
$12.62
$5.22
$27.38
$171.07M0.43155,733 shs166,315 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$2.89
+2.5%
$2.02
$0.81
$3.11
$95.42M-0.09149,248 shs20,126 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
0.00%+2.96%+17.87%+90.95%+1,391,999,900.00%
Cybin Inc. stock logo
CYBN
Cybin
-1.32%-6.20%-11.57%+57.40%+2,032.79%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+8.50%+3.90%+8.55%-1.95%+128.40%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-2.76%+9.73%+48.42%+163.55%+135.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
2.9135 of 5 stars
3.60.00.00.03.10.81.3
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.2731 of 5 stars
3.50.01.72.73.32.51.3
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
1.8692 of 5 stars
3.53.00.00.00.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
3.00
Buy$33.00153.07% Upside
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$85.001,014.02% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50116.01% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00142.21% Upside

Current Analyst Ratings Breakdown

Latest OKYO, CYBN, LFVN, and AARD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Cybin Inc. stock logo
CYBN
Cybin
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$73.00 ➝ $70.00
6/30/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
5/15/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
5/13/2025
Cybin Inc. stock logo
CYBN
Cybin
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/5/2025
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.89$0.92 per share15.41$2.05 per share6.89
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.20) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$20.59MN/A0.00N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6920.46N/A4.12%34.67%15.24%8/27/2025 (Estimated)
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$16.83MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)

Latest OKYO, CYBN, LFVN, and AARD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025N/A
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$0.70-$0.71-$0.01-$0.71N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.27%N/A26.09%3 Years
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A

Latest OKYO, CYBN, LFVN, and AARD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
25.86
25.86
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Cybin Inc. stock logo
CYBN
Cybin
17.94%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Cybin Inc. stock logo
CYBN
Cybin
15.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
1821.70 millionN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
5023.02 million17.96 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
733.84 million20.15 millionNot Optionable

Recent News About These Companies

OKYO moves toward FDA talks after eye drug trial – ICYMI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aardvark Therapeutics stock logo

Aardvark Therapeutics NASDAQ:AARD

$13.04 -0.88 (-6.32%)
As of 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Cybin stock logo

Cybin NYSE:CYBN

$7.63 -0.24 (-3.05%)
Closing price 04:00 PM Eastern
Extended Trading
$7.66 +0.03 (+0.39%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$14.12 +0.53 (+3.90%)
As of 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$2.89 +0.07 (+2.48%)
Closing price 03:59 PM Eastern
Extended Trading
$2.93 +0.04 (+1.25%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.